Menu
Menu
Menu
Telum Therapeutics Development Pipeline
Within our pipeline we have specific programs to treat serious multidrug-resistant
Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa
Program / Product
Pathogen
Discovery
Preclinical
Patent
Ongoing
Future
P001/TT206
(GN EPLE)
Enterobacteriaceae
(carbapenem-resistant,
3rd generation cephalosporin-
resistant),Pseudomonas
aeruginosa Acinetobacter
baumannii, Klebsiella spp.
Infections caused by Gram-negative
organisms, including cUTI, bacteremia,
respiratory infections, etc.
PCT/EP2021/056264
P002 (GN EPLE)
Pseudomonas aeruginosa
Cystic fribrosis
P003 (GN EPLE)
Staphylococcus aureus MRSA
P004 (GP EPLE)
Broad spectrum; ESKAPE
P005 (GN&GP EPLE)
Vancomycin-resistant Enterococci
Program / Product
P001/TT206 (GN EPLE)
Pathogen
Enterobacteriaceae (carbapenem-resistant, 3rd generation cephalosporin-resistant),Pseudomonas aeruginosa Acinetobacter baumannii, Klebsiella spp.
Discovery & Preclinical
Infections caused by Gram-negative organisms, including cUTI, bacteremia, respiratory infections, etc.
Patent
PCT/EP2021/056264
Program / Product
P002 (GN EPLE)
Pathogen
Pseudomonas aeruginosa
Discovery & Preclinical
Cystic fribrosis
Patent
Program / Product
P003 (GN EPLE)
Pathogen
Staphylococcus aureus MRSA
Discovery & Preclinical
Patent
Program / Product
P004 (GP EPLE)
Pathogen
Broad spectrum; ESKAPE
Discovery & Preclinical
Patent
Program / Product
P005 (GN&GP EPLE)
Pathogen
Vancomycin-resistant Enterococci
Discovery & Preclinical
Patent
Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp
